12.07.2012 - The French marine biotechnology specialist Hemarina SA has raised €6.3m to bring its first organ transplant product to market.
The company, founded in March 2007, is centred on the research and development of marine oxygen carriers for therapeutic and industrial applications. It develops extracellular haemoglobin for four core business programmes: organ transplantation and tissue conservation; blood oxygen carriers; infections and wound healing; and bio-production. The Morlaix based company is predicting to bring its first medical application product by end of 2013 in the field of kidney transplantation.
„This new round of investment shows the trust of our new partners and board members“, stated Franck Zal, CEO of Hemarina. The syndicate was led by Inserm Transfert Initiative and includes historical investors such as Finistère Angels, Armor Angels, XMP and Arkéa Capital Investissement; and also a new entrant which is a family office represented and mandated by M. Maurice Lesaffre.
Since last November, Hemarina receives research funding from the French National Research Agency (ANR) to push forward its lead candidate Hemo2Life solution for preserving kidney grafts. In a public private partnership, Hemarina will attempt to validate its oxygen carrier or the storage of kidney transplants in preservation solutions and machine perfusion systems. To do so, the French marine biotech specialist has teamed up with the INSERM U927 research unit “Ischemia-reperfusion in kidney transplantation” at the Poitiers University Hospital, and the Health, Life, and Agricultural Sciences Infrastructures (IBiSA) facility ‘Surgery, Experimentation, Transplantation’ in Surgères.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.